Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties

Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties

Over the past decade, CAR T cell therapy for patients with B cell malignancies has evolved from an experimental technique to a clinically feasible option. To date, four CAR T cell products specific for a B cell surface marker, CD19, have been approved by the FDA. Despite the spectacular rates of com...

Full description

Bibliographic Details
Main Authors: Tatyana Belovezhets, Sergey Kulemzin, Olga Volkova, Alexander Najakshin, Alexander Taranin, Andrey Gorchakov
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
CAR T cell
ALL
NHL
CD20
cancer immunotherapy
Online Access:https://www.mdpi.com/1422-0067/24/4/3698

Similar Items

Similar Items